drugset / Trial / NCT06077214

Liposomal Bupivacaine for Post-operative Pain Control in Adolescent Bariatric Patients

NCT06077214

Phase 1 Completed 9 enrolled Virginia Commonwealth University
RandomizedParallel-groupSingle-blindTreatment

Summary

Liposomal bupivacaine (trade name Exparel) is a local analgesic that is designed to produce more long-term pain control. Bupivacaine, a widely used local analgesic, is stored within liposomes, which break down in soft tissue over time. Typical length of therapeutic effect for standard bupivacaine is up to 6 hours. The liposomal formulation of bupivacaine, however, has a length of therapeutic effect of up to 72 hours. Typical post-operative incisional pain is known to last for several days in most cases and is thought to peak between 1-2 days after surgery. Therefore, the benefit of most short-acting local analgesics does not overlap with the period of most need.

Timeline

Start
2023-01-31
Primary completion
2024-08-20
Completion
2024-08-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified

Indications

No indication recorded.